Beam Therapeutics (BEAM) Equity Average (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of Equity Average data on file, last reported at $1.2 billion in Q1 2026.

• Equity Average for Q1 2026 came in at $1.2 billion, up 28.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 billion (up 28.97% YoY), and the FY2025 annual result was $986.0 million, up 14.99% from the prior year.
• Equity Average grew to $1.2 billion in Q1 2026 per BEAM's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Equity Average peaked at $1.2 billion in Q1 2026 and troughed at $724.0 million in Q4 2022.
• A 5-year average of $887.0 million and a median of $827.9 million in 2022 frame the typical range for Equity Average.
• On a YoY basis, Equity Average climbed as much as 147.88% in 2022 and fell as far as 13.84% in 2022.
• A 5-year view of Equity Average shows it stood at $724.0 million in 2022, then gained by 21.57% to $880.1 million in 2023, then fell by 13.37% to $762.4 million in 2024, then surged by 44.56% to $1.1 billion in 2025, then increased by 9.0% to $1.2 billion in 2026.
• Business Quant data shows BEAM's Equity Average at $1.2 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.0 billion in Q3 2025.